Because they evaluate the effects of treatments on physical, psychological and social dimensions of health from the unique perspective of the patient, health-related quality of life (HRQOL) instruments have become major outcome measures in randomized clinical trials (RCTs). 1, 2 Over the past two decades, HRQOL has become an established outcome measure in clinical research on multiple sclerosis (MS), with the first disease-specific inventories being published from 1995 on. 3 HRQOL endpoints are important in trials of MS disease-modifying drugs as they make it possible to better understand the efficacy and tolerability of these medications which must be integrated with the information provided by the other outcome measures. For nonpharmacological and symptomatic treatments, HRQOL and other patient-reported outcomes are clearly of paramount importance.
In this issue of the Multiple Sclerosis Journal, Kuspinar et al. publish a systematic review of the effects of non-disease-modifying interventions on HRQOL in people with MS. 4 Their quantitative review of 39 RCTs and 6 intervention categories found pooled effect sizes (ESs) that ranged from negligible (7 RCTs, ES 0.16, 95% confidence interval [CI] -0.08 to 0.40) for complementary and alternative medicines, to moderate (3 RCTs, ES 0.69, 95% CI 0.45-0.91) for psychological interventions on mood symptoms, which provided useful indications of the clinical significance of these types of intervention, and importantly suggested sample sizes for future trials.
Kuspinar and colleague's qualitative review presented a 'risk of bias' rating based on five items comprising randomization (two items), blinding (two items) and method of analysis. They found that only 49% of trials provided information on allocation concealment, while 69% reported that outcome assessment was blinded. Figures were better for allocation sequence generation (80%), intention-to-treat analysis (85%) and participant and personnel blinding (100% of pharmacologic trials).
However, a number of important aspects of the HRQOL instruments themselves were not systematically evaluated by Kuspinar and colleagues in their otherwise excellent study. For example, the criteria used to evaluate, report and interpret HRQOL data were not analysed. 5 Although all but two of the trials were published after 2000, only a third employed MS-specific instruments. Half employed generic inventories, and the rest employed a disparate assortment of instruments ranging through global assessment, ad hoc, domain-specific (one study) and utility-focused (EuroQol-5D, one study) inventories. Choosing a validated instrument that addresses the pertinent HRQOL domains, together with an appropriate prospective analysis plan, are crucial for good trial design. For the 13 trials that used HRQOL as primary (n = 8) or co-primary (n = 5) endpoint, it seems essential to assess how many provided a clear rationale for the HRQOL measure they employed, how many reported an a priori study hypothesis, and how many pre-specified statistical endpoints and analyses in order to avoid multiple statistical comparisons, selective reporting of results and data mining (particularly important with multidimensional instruments). 5 Citing evidence of an instrument's clinimetric properties (chiefly reliability and responsiveness), particularly those pertinent to the specific context or study population, is also essential. Furthermore a linguistically validated version of the instrument should be used, and administered correctly. 3, 5 It is also important that the timing of administration of the HRQOL is appropriate: there must be sufficient time from intervention to outcome assessment (so that HRQOL changes can take place) and adequate follow up (to assess the sustainability of effects). Finally, HRQOL findings should be interpreted in the context of the other trial outcomes. 5 It is noteworthy that over 80% of the RCTs included in Kuspinar et al.'s review were on non-pharmacologic treatments, a wide range of which were covered. Particular issues of non-pharmacologic RCTs include documentation of the theory at the base of the intervention, adequate description of content and care provider expertise. Moreover, participant and personnel blinding is often impossible or unethical. 6 To conclude, Kuspinar et al.'s study highlights the reality that HRQOL measures are now established in MS trials; however, careful analysis also reveals that choosing the appropriate instrument for a particular trial objective is still an unresolved problem, and that the current standard of reporting is less than ideal. The assessment of HRQOL in MS trials is time-consuming and costly: inadequate conception, management, analysis and reporting devalue HRQOL evidence and compromise its ability to inform clinical decision-making, patient counselling, practice guidelines and health policies. A CONSORT extension of criteria for HRQOL trial reporting is currently being
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7595M SJ181210.1177/1352458512447595SolariMultiple Sclerosis Journal Editorial developed. 7 In the meantime, HRQOL quality reporting criteria originally devised for trials on other medical conditions could usefully be applied to MS. 8, 9 It would also be useful to apply these criteria to systematic reviews on the effects of MS disease-modifying treatments on HRQOL: such reviews are at present conspicuous by their absence. 10
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